AAPL   320.12 (+0.39%)
MSFT   183.10 (-0.22%)
FB   235.97 (+0.45%)
GOOGL   1,436.43 (+1.64%)
AMZN   2,439.66 (+0.11%)
NVDA   352.29 (-2.43%)
CGC   20.14 (+3.66%)
TSLA   822.06 (+0.63%)
AMD   54.22 (-1.72%)
T   31.08 (+4.02%)
ACB   15.74 (-1.69%)
F   5.87 (+3.89%)
DIS   121.97 (+3.35%)
NFLX   416.27 (-3.04%)
BAC   24.42 (+7.77%)
BA   144.96 (+5.40%)
AAPL   320.12 (+0.39%)
MSFT   183.10 (-0.22%)
FB   235.97 (+0.45%)
GOOGL   1,436.43 (+1.64%)
AMZN   2,439.66 (+0.11%)
NVDA   352.29 (-2.43%)
CGC   20.14 (+3.66%)
TSLA   822.06 (+0.63%)
AMD   54.22 (-1.72%)
T   31.08 (+4.02%)
ACB   15.74 (-1.69%)
F   5.87 (+3.89%)
DIS   121.97 (+3.35%)
NFLX   416.27 (-3.04%)
BAC   24.42 (+7.77%)
BA   144.96 (+5.40%)
AAPL   320.12 (+0.39%)
MSFT   183.10 (-0.22%)
FB   235.97 (+0.45%)
GOOGL   1,436.43 (+1.64%)
AMZN   2,439.66 (+0.11%)
NVDA   352.29 (-2.43%)
CGC   20.14 (+3.66%)
TSLA   822.06 (+0.63%)
AMD   54.22 (-1.72%)
T   31.08 (+4.02%)
ACB   15.74 (-1.69%)
F   5.87 (+3.89%)
DIS   121.97 (+3.35%)
NFLX   416.27 (-3.04%)
BAC   24.42 (+7.77%)
BA   144.96 (+5.40%)
AAPL   320.12 (+0.39%)
MSFT   183.10 (-0.22%)
FB   235.97 (+0.45%)
GOOGL   1,436.43 (+1.64%)
AMZN   2,439.66 (+0.11%)
NVDA   352.29 (-2.43%)
CGC   20.14 (+3.66%)
TSLA   822.06 (+0.63%)
AMD   54.22 (-1.72%)
T   31.08 (+4.02%)
ACB   15.74 (-1.69%)
F   5.87 (+3.89%)
DIS   121.97 (+3.35%)
NFLX   416.27 (-3.04%)
BAC   24.42 (+7.77%)
BA   144.96 (+5.40%)
Log in

NASDAQ:NTLAIntellia Therapeutics Stock Price, Forecast & News

$19.97
-1.02 (-4.86 %)
(As of 05/26/2020 01:54 PM ET)
Add
Compare
Today's Range
$19.75
Now: $19.97
$21.60
50-Day Range
$11.90
MA: $14.81
$20.99
52-Week Range
$9.18
Now: $19.97
$21.00
Volume114,593 shs
Average Volume854,522 shs
Market Capitalization$1.03 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.63
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Ospedale San Raffaele; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
Intellia Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTLA
CUSIPN/A
Phone857-285-6200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$43.10 million
Book Value$5.52 per share

Profitability

Net Income$-99,530,000.00
Net Margins-239.98%

Miscellaneous

Employees211
Market Cap$1.03 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive NTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.

Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions

How has Intellia Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NTLA stock has increased by 56.1% and is now trading at $19.86. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Intellia Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Intellia Therapeutics.

When is Intellia Therapeutics' next earnings date?

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Intellia Therapeutics.

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics Inc (NASDAQ:NTLA) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.24. The company earned $12.92 million during the quarter, compared to analyst estimates of $21.98 million. Intellia Therapeutics had a negative net margin of 239.98% and a negative return on equity of 40.89%. The business's revenue was up 23.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.49) earnings per share. View Intellia Therapeutics' earnings history.

What price target have analysts set for NTLA?

7 brokers have issued 1 year price objectives for Intellia Therapeutics' stock. Their forecasts range from $16.00 to $57.50. On average, they expect Intellia Therapeutics' share price to reach $26.42 in the next twelve months. This suggests a possible upside of 33.0% from the stock's current price. View analysts' price targets for Intellia Therapeutics.

Has Intellia Therapeutics been receiving favorable news coverage?

News articles about NTLA stock have trended positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Intellia Therapeutics earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutIntellia Therapeutics.

Who are some of Intellia Therapeutics' key competitors?

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Square (SQ), InVitae (NVTA), Advanced Micro Devices (AMD), Cisco Systems (CSCO) and Sangamo Therapeutics (SGMO).

Who are Intellia Therapeutics' key executives?

Intellia Therapeutics' management team includes the following people:
  • Dr. John M. Leonard, Pres, CEO & Director (Age 62)
  • Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 46)
  • Mr. José E. Rivera, Exec. VP & Gen. Counsel (Age 53)
  • Ms. Rachel Haurwitz Ph.D., Co-Founder (Age 33)
  • Mr. Andrew May Ph.D., Founder and Member of Scientific Advisor Board

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Nikko Asset Management Americas Inc. (13.81%), Sumitomo Mitsui Trust Holdings Inc. (14.51%), Nikko Asset Management Americas Inc. (13.81%), BlackRock Inc. (7.38%), State Street Corp (3.36%) and Morgan Stanley (1.26%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier and Jean Francois Formela. View institutional ownership trends for Intellia Therapeutics.

Which major investors are selling Intellia Therapeutics stock?

NTLA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Nuveen Asset Management LLC, Two Sigma Investments LP, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Bank of New York Mellon Corp, and Deutsche Bank AG. View insider buying and selling activity for Intellia Therapeutics.

Which major investors are buying Intellia Therapeutics stock?

NTLA stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, BlackRock Inc., JPMorgan Chase & Co., Geode Capital Management LLC, Aigen Investment Management LP, State Street Corp, Los Angeles Capital Management & Equity Research Inc., and Two Sigma Advisers LP. View insider buying and selling activity for Intellia Therapeutics.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $19.86.

How big of a company is Intellia Therapeutics?

Intellia Therapeutics has a market capitalization of $1.02 billion and generates $43.10 million in revenue each year. The company earns $-99,530,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Intellia Therapeutics employs 211 workers across the globe.

What is Intellia Therapeutics' official website?

The official website for Intellia Therapeutics is www.intelliatx.com.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.